Assessment of Annona muricata Phytochemicals as 17β‐HSD1 Inhibitors through Molecular Docking, Dynamics Simulation, DFT, and ADMET Analyses
Open Access
- 12 November 2025
- journal article
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 29 (21) , e70904
Abstract
Breast cancer remains a leading cause of female mortality, largely sustained by local oestrogen production. The enzyme 17β‐hydroxysteroid dehydrogenase type 1 (17β‐HSD1) is an enzyme involved in the oestrogen biosynthesis pathway, particularly in the conversion of estrone to estradiol, and is overexpressed in conditions such as breast cancer. Therefore, it is considered a relevant target for drug development. We evaluated phytocompounds from Annona muricata as prospective 17β‐HSD1 inhibitors through an integrated in silico workflow. Twelve reported constituents (myristic acid, myrcene, palmitic acid, hexanoic acid, pentadecane, methyl 3‐phenylpropionate, butyric acid, linalool, reticuline, phytol, camphene and calamenene) were geometry‐optimised by density‐functional theory, docked against 17β‐HSD1 (PDB 3HB5), and screened for drug‐likeness and ADMET liabilities. The top‐ranked complexes—reticuline (ΔG_pred = −8.4 kcal mol −1 ) and calamenene (−7.7 kcal mol −1 )—scored more favourably than the reference epirubicin (−5.7 kcal mol −1 ) and were subjected to 100 ns molecular‐dynamics simulations. Both ligands remained stably anchored within the catalytic pocket, with root mean square deviation (RMSD) fluctuations below 2.0 Å, yet MM‐PBSA binding free energies (reticuline −27 kJ mol −1 ; calamenene −9 kJ mol −1 ) did not surpass the reference. ADMET profiling predicted acceptable Caco‐2 permeability (0.92–0.94), and only moderate hERG liability, but also signalled potential DILI and carcinogenicity alerts that warrant caution. Reticuline and calamenene fulfilled all of Lipinski's criteria, with the exception of logP in the case of calamenene. Collectively, these findings nominate reticuline and calamenene as promising lead scaffolds for selective intracellular suppression of oestrogen biosynthesis. Experimental validation (enzyme kinetics, cell‐based assays and pharmacokinetic studies) is warranted to confirm their clinical potential in oestrogen‐dependent breast cancer.Keywords
This publication has 93 references indexed in Scilit:
- Bio3d: an R package for the comparative analysis of protein structuresBioinformatics, 2006
- Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancerThe Journal of Steroid Biochemistry and Molecular Biology, 2005
- Overview of Steroidogenic Enzymes in the Pathway from Cholesterol to Active Steroid HormonesEndocrine Reviews, 2004
- Human Carcinogenic Risk Evaluation, Part III: Assessing Cancer Hazard and Risk in Human Drug DevelopmentToxicological Sciences, 2004
- Molecular Dynamics Simulations and Thermodynamics Analysis of DNA−Drug Complexes. Minor Groove Binding between 4‘,6-Diamidino-2-phenylindole and DNA Duplexes in SolutionJournal of the American Chemical Society, 2003
- Mechanisms of Estrogen ActionPhysiological Reviews, 2001
- 17 β -Hydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma: a correlation to clinicopathological parametersBritish Journal of Cancer, 2000
- Basic Guide to the Mechanisms of Antiestrogen ActionPharmacological Reviews, 1998
- VMD: Visual molecular dynamicsJournal of Molecular Graphics, 1996
- Multiple fatty acid binding to albumin in human blood plasmaEuropean Journal of Biochemistry, 1990